Titre :

Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network

Auteur(s) :

De Pinieux, Gonzague [Auteur]
Karanian, Marie [Auteur]
Le Loarer, Francois [Auteur]
Le Guellec, Sophie [Auteur]
Chabaud, Sylvie [Auteur]
Terrier, Philippe [Auteur]
Bouvier, Corinne [Auteur]
Batistella, Maxime [Auteur]
Neuville, Agnes [Auteur]
Robin, Yves-Marie [Auteur]
Institut de Pathologie [CHU Lille]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Emile, Jean-Francois [Auteur]
Moreau, Anne [Auteur]
Larousserie, Frederique [Auteur]
Leroux, Agnes [Auteur]
Stock, Nathalie [Auteur]
Lae, Marick [Auteur]
Collin, Francoise [Auteur]
Weinbreck, Nicolas [Auteur]
Aubert, Sebastien [Auteur]
Institut de Pathologie [CHU Lille]
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Mishellany, Florence [Auteur]
Charon-Barra, Celine [Auteur]
Croce, Sabrina [Auteur]
Doucet, Laurent [Auteur]
Quintin-Rouet, Isabelle [Auteur]
Chateau, Marie-Christine [Auteur]
Bazille, Celine [Auteur]
Valo, Isabelle [Auteur]
Chetaille, Bruno [Auteur]
Ortonne, Nicolas [Auteur]
Brouchet, Anne [Auteur]
Rochaix, Philippe [Auteur]
Demuret, Anne [Auteur]
Ghnassia, Jean-Pierre [Auteur]
Mescam, Lenaig [Auteur]
Macagno, Nicolas [Auteur]
Birtwisle-Peyrottes, Isabelle [Auteur]
Delfour, Christophe [Auteur]
Angot, Emilie [Auteur]
Pommepuy, Isabelle [Auteur]
Ranchere, Dominique [Auteur]
Chemin-Airiau, Claire [Auteur]
Jean-Denis, Myriam [Auteur]
Fayet, Yohan [Auteur]
Courreges, Jean-Baptiste [Auteur]
Mesli, Nouria [Auteur]
Berchoud, Juliane [Auteur]
Toulmonde, Maud [Auteur]
Italiano, Antoine [Auteur]
Le Cesne, Axel [Auteur]
Penel, Nicolas [Auteur]
Institut de Pathologie [CHU Lille]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Ducimetiere, Francoise [Auteur]
Gouin, Francois [Auteur]
Coindre, Jean-Michel [Auteur]
Blay, Jean-Yves [Auteur]

Titre de la revue :

PLoS ONE

Nom court de la revue :

PLoS One

Numéro :

16

Pagination :

e0246958

Date de publication :

2021-02-25

ISSN :

1932-6203

Mot(s)-clé(s) en anglais :

Sarcoma
Metastatic tumors
Cancer epidemiology
Angiosarcoma
Neurological tumors
Skin tumors
Gastrointestinal cancers
Malignant tumors

Discipline(s) HAL :

Sciences du Vivant [q-bio]
Sciences du Vivant [q-bio]/Cancer
Sciences du Vivant [q-bio]/Médecine humaine et pathologie

Résumé en anglais : [en]

BACKGROUND: Since 2010, nationwide networks of reference centers for sarcomas (RREPS/NETSARC/RESOS) collected and prospectively reviewed all cases of sarcomas and connective tumors of intermediate malignancy (TIM) in France. ...
Lire la suite >BACKGROUND: Since 2010, nationwide networks of reference centers for sarcomas (RREPS/NETSARC/RESOS) collected and prospectively reviewed all cases of sarcomas and connective tumors of intermediate malignancy (TIM) in France. METHODS: The nationwide incidence of sarcoma or TIM (2013-2016) was measured using the 2013 WHO classification and confirmed by a second independent review by expert pathologists. Simple clinical characteristics, yearly variations and correlation of incidence with published clinical trials are presented and analyzed. RESULTS: Over 150 different histological subtypes are reported from the 25172 patients with sarcomas (n = 18712, 74,3%) or TIM (n = 6460, 25.7%), with n = 5838, n = 6153, n = 6654, and n = 6527 yearly cases from 2013 to 2016. Over these 4 years, the yearly incidence of sarcomas and TIM was therefore 70.7 and 24.4 respectively, with a combined incidence of 95.1/106/year, higher than previously reported. GIST, liposarcoma, leiomyosarcomas, undifferentiated sarcomas represented 13%, 13%, 11% and 11% of tumors. Only GIST, as a single entity had a yearly incidence above 10/106/year. There were respectively 30, 64 and 66 different histological subtypes of sarcomas or TIM with an incidence ranging from 10 to 1/106, 1-0.1/106, or < 0.1/106/year respectively. The 2 latter incidence groups represented 21% of the patients with 130 histotypes. Published phase III and phase II clinical trials (p<10-6) are significantly higher with sarcomas subtypes with an incidence above 1/106 per. CONCLUSIONS: This nationwide registry of sarcoma patients, with exhaustive histology review by sarcoma experts, shows that the incidence of sarcoma and TIM is higher than reported, and that tumors with a very low incidence (1<106/year) are less likely to be included in clinical trials.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Projet ANR :

Institut François Rabelais pour la recherche multidisciplinaire sur le cancer
Development Cancer and Targeted Therapies
Clinical proof of concept of dependence receptor targeting in gynecological Oncology

Établissement(s) :

CHU Lille
CNRS
ENSCL
INRA
INSERM
Université de Lille

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
• Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Date de dépôt :

2022-06-15T13:58:09Z
2023-02-20T11:56:02Z
2023-02-20T12:05:32Z